400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast ...

HAWTHORNE, Calif.--(BUSINESS WIRE)--Teledyne Relays, a leading provider of cutting-edge relay solutions, introduces its new 3-Phase Monitoring Relay. The new 3-Phase ...

The decision was supported by clinical data from the Phase 1/2 ReDiscover trial and advances the ongoing Phase 3 trial, ReDiscover-2. Additionally, Guggenheim has raised its price target for Relay ...

Carlo Gavazzi offers the new DPD Series Three-Phase Monitoring Relay with NFC configuration; this relay provides the utmost flexibility in very compact dimensions, as it offers a wide range of ...

Relay Therapeutics has beaten its survival goal in a first-in-human breast cancer study, positioning the biotech to move into a pivotal trial that could establish its candidate as a challenger to ...

BAODING, HEBEI, CHINA, January 21, 2026 /EINPresswire.com/ — As power systems worldwide evolve toward higher capacity, digital substations, and diversified energy ...

BAODING, HEBEI, CHINA, January 16, 2026 /EINPresswire.com/ — In the critical field of electrical maintenance and safety, the reliability of testing equipment ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...